182 related articles for article (PubMed ID: 17609924)
1. [Evaluation of biochemical bone metabolism parameters].
Hegele A; Olbert P; Wahl HG; Hofmann R
Urologe A; 2007 Sep; 46(9):1285-6. PubMed ID: 17609924
[No Abstract] [Full Text] [Related]
2. [Multimodal therapy of prostate cancer - 2 case reports].
Lamche M; Bauer WA; Schramek P
Wien Med Wochenschr; 2008; 158(11-12):303-6. PubMed ID: 18641930
[TBL] [Abstract][Full Text] [Related]
3. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
Schriefer P; Steurer S; Huland H; Graefen M
J Clin Oncol; 2012 Nov; 30(32):e341-4. PubMed ID: 23032622
[No Abstract] [Full Text] [Related]
4. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.
Loeb S; Makarov DV; Schaeffer EM; Humphreys EB; Walsh PC
J Urol; 2010 Jul; 184(1):157-61. PubMed ID: 20483148
[TBL] [Abstract][Full Text] [Related]
5. Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis.
Song C; Kang HC; Kim JS; Eom KY; Kim IA; Chung JB; Hong SK; Byun SS; Lee SE
Strahlenther Onkol; 2015 Oct; 191(10):801-9. PubMed ID: 26159555
[TBL] [Abstract][Full Text] [Related]
6. [Study of the hormone-refractory prostate cancer clinical practice in an anti-cancer center].
Zufferey L; Roques B; Fléchon A; Droz JP
Bull Cancer; 2001 Dec; 88(12):1213-21. PubMed ID: 11792613
[TBL] [Abstract][Full Text] [Related]
7. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
8. [Novelties in diagnostics and treatment of prostate cancer].
Riesz P; Nyírádi P
Orv Hetil; 2016 Mar; 157(11):410-4. PubMed ID: 26947089
[TBL] [Abstract][Full Text] [Related]
9. Is prostate-specific antigen a reliable marker of bone metastasisin patients with newly diagnosed cancer of the prostate?
Gontero P; Muir GH
Eur Urol; 1998 Dec; 34(6):518-9. PubMed ID: 9831795
[No Abstract] [Full Text] [Related]
10. Staging evaluation and follow-up of patients with advanced prostatic cancer.
Wajsman Z; Klimberg IW
Semin Urol; 1988 Nov; 6(4):249-61. PubMed ID: 3068764
[No Abstract] [Full Text] [Related]
11. [Sentinel lymph node dissection in prostate cancer. Experience after more than 800 interventions].
Weckermann D; Hamm M; Dorn R; Wagner T; Wawroschek F; Harzmann R
Urologe A; 2006 Jun; 45(6):723-7. PubMed ID: 16586052
[TBL] [Abstract][Full Text] [Related]
12. Re: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.
Maffezzini M
J Urol; 2005 Sep; 174(3):1151-2; author reply 1152. PubMed ID: 16094087
[No Abstract] [Full Text] [Related]
13. [Treatment strategy for prostate cancer].
Kakehi Y
Nihon Rinsho; 2002 Dec; 60 Suppl 11():170-6. PubMed ID: 12599566
[No Abstract] [Full Text] [Related]
14. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
[TBL] [Abstract][Full Text] [Related]
15. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin a in patients with androgen ablation refractory prostate cancer.
Di Silverio F; Sciarra A
J Urol; 2003 Nov; 170(5):1812-6. PubMed ID: 14532782
[TBL] [Abstract][Full Text] [Related]
17. Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Perry CJ; Sundar S
Clin Genitourin Cancer; 2012 Sep; 10(3):207-9. PubMed ID: 22445962
[No Abstract] [Full Text] [Related]
18. [Reliability of CT for determining lymphatic involvement in patients with prostate cancer].
Amo FH; Verdú Tartajo F; Díez Cordero JM; Lledó García E; Bueno Chomón G; Leal Hernández F
Arch Esp Urol; 1997 Jun; 50(5):464-8. PubMed ID: 9382588
[TBL] [Abstract][Full Text] [Related]
19. ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.
Sweeney CJ
Clin Adv Hematol Oncol; 2006 Aug; 4(8):588-90. PubMed ID: 17111557
[No Abstract] [Full Text] [Related]
20. Undetectable prostate specific antigen in disseminated prostate cancer.
Beardo P; Fernández PL; Corral JM; Filella X; Alcover J
J Urol; 2001 Sep; 166(3):993. PubMed ID: 11490269
[No Abstract] [Full Text] [Related]
[Next] [New Search]
